key: cord-0275340-op5g0dyb authors: Doll, M. K. K.; Pettigrew, S. M.; Ma, J.; Verma, A. title: Effects of Confounding Bias in COVID-19 and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors date: 2021-10-25 journal: nan DOI: 10.1101/2021.10.22.21265390 sha: 27079ce66d81ed4279e370676f3d3c00c1a3a2d2 doc_id: 275340 cord_uid: op5g0dyb Background: The test-negative design is commonly used to estimate influenza and COVID-19 vaccine effectiveness (VE). In these studies, correlated COVID-19 and influenza vaccine behaviors may introduce a confounding bias where controls are included with the other vaccine-preventable acute respiratory illness (ARI). We quantified the impact of this bias on VE estimates in studies where this bias is not addressed. Methods: We simulated study populations under varying vaccination probabilities, COVID-19 VE, influenza VE, and proportions of controls included with the other vaccine-preventable ARI. Mean bias was calculated as the difference between true and estimated VE. Absolute mean bias in VE estimates was classified as low (<10%), moderate (10% to <20%), and high ([≥]20%). Results: Where vaccination probabilities are positively correlated, COVID-19 and influenza VE test-negative studies with influenza and SARS-CoV-2 ARI controls, respectively, underestimate VE. For COVID-19 VE studies, mean bias was low for all scenarios where influenza represented [≤]50% of controls. For influenza VE studies, mean bias was low for all scenarios where SARS-CoV-2 represented [≤]10% of controls. Although bias was driven by the conditional probability of vaccination, low VE of the vaccine of interest and high VE of the confounding vaccine increase its magnitude. Conclusions: Where a low percentage of controls are included with the other vaccine-preventable ARI, bias in COVID-19 and influenza VE estimates is low. However, influenza VE estimates are likely more susceptible to bias. Researchers should consider potential bias and its implications in their respective study settings to make informed methodological decisions in test-negative VE studies. Phase four observational studies are essential to examine the direct effects of vaccination in a real-world setting. Due to its relative simplicity, the test-negative study design is the predominant observational design used to estimate vaccine effectiveness (VE) for influenza, 1 and increasingly, COVID-19. [2] [3] [4] In these studies, test-negative participants are persons who seek healthcare for an acute respiratory illness (ARI) and are tested for the disease of interest. Participants who test positive are classified as "cases", while participants who test negative are classified as "controls". VE is estimated using the formula (1 − ) * 100, where the odds ratio compares the vaccination odds between cases and controls. 5 Similar to other case-control studies, controls in the test-negative design are used as a proxy to estimate the true vaccination odds in the source population of cases. 5, 6 Since COVID-19 and influenza VE test-negative designs select ARI controls who are negative for the disease of interest, a foundational assumption of these designs is that the risks of alternative causes of ARI are independent of exposure status (i.e., vaccination). 7 Where this assumption is violated, VE estimates will be biased unless independence is established by deconfounding either in the statistical analysis or the modification of the study design. To date, work examining the validity of this assumption in influenza test-negative VE studies has focused on direct, biological mechanisms by which influenza and/or influenza vaccination may influence the risk of alternate causes of ARI. 8, 9 However, a relationship between influenza vaccination and alternate ARI need not be causally-related to violate this assumption; in fact, a violation can also occur due to a relationship established by an indirect, confounding pathway. 10 COVID-19 VE studies include persons with the other vaccine-preventable ARI, vaccination for these diseases acts as a confounder. In these studies, where this confounder is unaccounted for, the fundamental assumption of exposure independence in control selection is violated, leading to bias in VE estimates. Since SARS-CoV-2 and influenza are likely to co-circulate in upcoming influenza seasons, it is important to understand the scope and magnitude of this confounding bias on COVID-19 and influenza VE estimates. Here, we aim to contribute to this knowledge by: (i) examining its theoretical basis and deconfounding methods to remove bias, and (ii) quantifying bias in COVID-19 and influenza VE estimates using simulations, where this bias is not otherwise addressed. In Figure 1a , we examine the theoretical basis for bias from inclusion of controls with a Given the confounding structure in Figure 1a , we propose two potential options to mitigate confounding bias in COVID-19 and influenza test-negative designs, where co-circulation of SARS-CoV-2 and influenza is present: (i) deconfounding in the analysis, or (ii) deconfounding in the study design. Alternatively, a third potential option is to ignore the bias if it is anticipated to be sufficiently small, and not meaningful to VE estimates. We address options (i) and (ii) in the following section, and in subsequent sections, quantify bias using simulations to understand the implications of option (iii). (i) Deconfounding in the analysis: In Figure 1b , we demonstrate how the assumption of exposure independence can be restored in a COVID-19 VE study analysis by statistical adjustment or stratification for influenza vaccination. Similarly, in Figure 1c , we demonstrate how statistical adjustment for COVID-19 vaccination in the analysis can also restore the validity of this assumption in influenza VE studies. Although these mechanisms can recover unbiased estimates of VE, it is important to note that they may interfere with the "efficiency principle" in case-control designs proposed by Wacholder et al. 15 Where and are highly correlated, statistical adjustment for the confounder in an influenza VE study, or in a COVID-19 VE study, also reduces the conditional variability of the exposure in the strata of the confounder. 15 Therefore, although adjustment removes bias, precision of VE estimates may also be reduced. 15 This may be of particular concern in studies that aim to explore VE among subpopulations of interest or the effect of waning VE, which require additional statistical power. (ii) Deconfounding in the design: As an alternative to deconfounding in the analysis, (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; method of restriction is to enroll controls who test positive for a different cause of ARI, which is presumed independent of the exposure probability. As previously mentioned, a third option is to ignore bias if it is anticipated to be sufficiently small and not meaningful to VE estimates. However, it is important to understand the potential magnitude of confounding bias to make this determination. We used simulated populations where COVID-19 and influenza vaccination were positively correlated to estimate mean bias in COVID-19 and influenza VE estimates. While simulations were performed for each disease separately, the following common input parameters were included in both analyses: = influenza vaccination coverage = COVID-19 vaccination coverage = incidence proportion (risk) of medically-attended influenza ARI in the unvaccinated population = incidence proportion (risk) of medically-attended COVID-19 ARI in the unvaccinated population = true influenza VE to prevent medically-attended influenza ARI = true COVID-19 VE to prevent medically-attended COVID-19 ARI = proportion of ARI controls who represent the alternate vaccinepreventable ARI For all simulations, we assumed = 55% and = 70%, which approximates 2020-21 influenza vaccination coverage and fully-vaccinated COVID-19 vaccine coverage among U.S. adults. 16, 17 We also assumed = 5% and = 5%, based upon previous simulations investigating bias in test-negative designs. 1 We examined three scenarios for of 40%, 50%, and 60% effectiveness against medicallyattended influenza ARI, consistent with data from recent influenza seasons. 18 Furthermore, for , we examined the 3 scenarios of 70%, 80%, and 90% effectiveness against medically-attended SARS-CoV-2 ARI, similar to estimates from All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; recent VE studies. 4, [19] [20] [21] [22] For each scenario, we examined a range for of 0, 0.1, 0.25, 0.5, 0.75, 0.9 and 1.0. In addition to these inputs, we included an input variable representing the conditional probability of vaccination given vaccination with the other ARI vaccine. Specifically, | was used to simulate bias in COVID-19 VE studies, and | was used to simulate bias in influenza VE studies. These variables were defined as the following: . To explore bias in influenza VE test-negative designs, we modified the three steps to the following: simulation of (i) the marginal probabilities of COVID-19 and All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In all scenarios, the inclusion of influenza test-negative controls underestimated true COVID-19 VE. Figure 2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this paper, we provide the theoretical basis and quantification of confounding bias in (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. While our findings may be viewed as reassuring regarding bias in COVID-19 test-negative VE studies, these results are subject to several important limitations. First, we caution that our simulations examine bias scenarios we considered likely in the general population based on empiric U.S. data; however, we did not explore plausible scenarios by subpopulation. It is possible that some subpopulations, such as older persons or persons who are at higher risk of severe disease, may have a higher conditional probability of COVID-19 vaccination, given influenza vaccination status; this difference could thus, cause greater bias than we observed in our estimates. Similarly, regional variation in COVID-19 and influenza vaccination coverage may also affect the conditional probability of vaccination. Currently, lower uptake of COVID-19 vaccination in some southern U.S. states more closely aligns with influenza vaccination coverage in these regions. 16, 17 These differences may also increase the conditional probability of vaccination, and thus, represent a setting where greater bias in COVID-19 VE estimates can occur. Both examples demonstrate that bias in VE estimates may be differential by subpopulation, which may be important for the interpretation of VE results. Additionally, even where the conditional probability of vaccination is the same, we found that bias can vary by true VE. In the case of COVID-19, where true VE is likely to vary by vaccine product, 4, 20 bias in VE estimates will be differential by vaccine product. For similar reasons, bias in COVID-19 VE estimates may also be differential by outcome, such as symptomatic disease versus hospitalization. Collectively, these examples may highlight the importance of adopting deconfounding methods to promote comparability in VE estimates across subpopulations or outcomes, even in situations where overall bias is expected to be low. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; It is important to acknowledge a deconfounding requirement may impact the feasibility of a test-negative study, i.e., a design commonly implemented using administrative data. 2, 4 In particular, a challenge of deconfounding in the analysis is that it requires measurement of both vaccinations, which may not both be reliably recorded in a vaccine registry. Further, deconfounding by study design requires the additional costs associated with testing for other pathogen(s), unless this testing is routinely performed. However, where additional efforts are made to implement these methods, an advantage is that both influenza and COVID-19 test-negative VE studies can be run in parallel without much extra additional effort. In conclusion, our work suggests bias is low in VE estimates derived from COVID-19 and influenza test-negative studies that include influenza and SARS-CoV-2 controls, respectively, in situations where these controls represent a low proportion of total testnegative controls. Nonetheless, we encourage researchers to thoughtfully consider this potential bias and its implications in their respective study settings. Where researchers determine bias is unlikely to be meaningful and do not undertake deconfounding methods to remove bias, adequate justification should be provided to promote critical interpretation and confidence in study results. MKD designed the study and drafted the article. SMP helped to interpret the findings and critically reviewed the manuscript. AV and JM directed the analytical strategy, helped to interpret the findings, and critically reviewed the manuscript. The datasets that were used to inform the marginal probabilities of influenza and COVID-19 vaccination were derived from sources in the public domain. 14 Supplementary data are available in Supplemental Appendix 1. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; in an influenza VE testnegative study that includes SARS-CoV-2 controls closes the confounding pathway from All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Since bias in VE estimates is driven by the relationship between COVID-19 and influenza vaccine uptake, we examined the conditional probabilities of COVID-19 and influenza vaccination using data from U.S. IPSOS Knowledge Panel and NORC AmeriSpeak Omnibus Surveys. 14 Briefly, the U.S. Centers for Disease Control and Prevention sponsored questions on these surveys pertaining to influenza and COVID-19 vaccination coverage and intent. 14 Both surveys aimed to recruit nationally representative panels of the U.S. population, and are administered twice per month to assess national influenza vaccination coverage and intent among U.S. adults. 14 We used publicly-available data from these surveys collected from September 10-13, 2021 for our analyses, which represented the most recent survey data at the time of our analysis. Survey questions asked participants about their COVID-19 vaccination uptake and intent, as well as their influenza vaccination uptake and intent. Specifically, for COVID-19 vaccination, three categories of uptake/intent were provided: (i) vaccinated or definitely plan to get vaccinated for COVID-19, (ii) probably will get vaccinated for COVID-19 or are unsure, and (iii) probably or definitely will not get vaccinated for COVID-19. For influenza vaccination, four categories of uptake/intent were provided: (i) vaccinated for flu, (ii) intend to get vaccinated for flu, (iii) not sure about getting vaccinated for flu, and (iv) do not intend to get vaccinated for flu. To understand the impact of correlated COVID-19 and influenza vaccination behaviors, we estimated the conditional probabilities of: (i) COVID-19 vaccination, given influenza vaccination status, and (ii) influenza vaccination, given COVID-19 vaccination status using survey data. We characterized each of these conditional probabilities as a risk ratio, where: i. | = risk ratio comparing the uptake (risk) of COVID-19 vaccine between persons who did and did not receive influenza vaccination ii. | = risk ratio comparing the uptake (risk) of flu vaccine between persons who did and did not receive a COVID-19 vaccination All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; Table 1 . Definitions for influenza vaccination and COVID-19 vaccination applied to survey data. Definition # Survey categories used to define vaccination status = Yes b) probably will get vaccinated for COVID-19 or are unsure All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 25, 2021. ; https://doi.org/10.1101/2021.10.22.21265390 doi: medRxiv preprint Effects of imperfect test sensitivity and specificity on observational studies of influenza vaccine effectiveness SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting Covid-19 Vaccine Effectiveness and the Test-Negative Design Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings Design and analysis of vaccine studies Modern epidemiology The test-negative design for estimating influenza vaccine effectiveness Influenza vaccination and respiratory virus interference among Department of Defense personnel during the 2017-2018 influenza season Influenza Vaccine Does Not Increase the Risk of Coronavirus or Other Noninfluenza Respiratory Viruses: Retrospective Analysis From Canada Selection of controls in case-control studies: II. Types of controls A Comparison of the Level of Acceptance and Hesitancy towards the Influenza Vaccine and the Forthcoming COVID-19 Vaccine in the Healthcare workers' (HCWs) attitudes and related factors towards COVID-19 vaccination: a rapid systematic review Cumulative Influenza Vaccination Coverage and Intent for Vaccination Among Adults 18 Years and Older by Age, Race/Ethnicity, and COVID-19 Vaccination and Intent Selection of controls in case-control studies: I. Principles Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States: Fully Vaccinated Population >=18 Years of Age National Center for Immunization and Respiratory Diseases Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight U.S. Locations Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B. 1.617. 2 (Delta) Variant-National Healthcare Safety Network Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults-United States All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Given that answer categories for influenza or COVID-19 vaccination survey questions did not represent participant's definitive influenza and COVID-19 vaccination status, we estimated | and | using two different definitions for COVID-19 vaccine uptake and two different definitions for influenza vaccine (Supplemental Table 1 ). For each combination of COVID-19 and influenza definitions (total n = 4), we used